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Abstract
Background: The hedgehog (Hh) pathway has been implicated in the pathogenesis of cancer including pancreatic ductal
adenocarcinoma (PDAC). Recent studies have suggested that the oncogenic function of Hh in PDAC involves signaling in
the stromal cells rather than cell autonomous effects on the tumor cells. However, the origin and nature of the stromal cell
type(s) that are responsive to Hh signaling remained unknown. Since Hh signaling plays a crucial role during embryonic and
postnatal vasculogenesis, we speculated that Hh ligand may act on tumor vasculature specifically focusing on bone marrow
(BM)-derived cells.
Methodology/Principal Findings: Cyclopamine was utilized to inhibit the Hh pathway in human PDAC cell lines and their
xenografts. BM transplants, co-culture systems of tumor cells and BM-derived pro-angiogenic cells (BMPCs) were employed
to assess the role of tumor-derived Hh in regulating the BM compartment and the contribution of BM-derived cells to
angiogenesis in PDAC. Cyclopamine administration attenuated Hh signaling in the stroma rather than in the cancer cells as
reflected by decreased expression of full length Gli2 protein and Gli1 mRNA specifically in the compartment. Cyclopamine
inhibited the growth of PDAC xenografts in association with regression of the tumor vasculature and reduced homing of
BM-derived cells to the tumor. Host-derived Ang-1 and IGF-1 mRNA levels were downregulated by cyclopamine in the
tumor xenografts. In vitro co-culture and matrigel plug assays demonstrated that PDAC cell-derived Shh induced Ang-1 and
IGF-1 production in BMPCs, resulting in their enhanced migration and capillary morphogenesis activity.
Conclusions/Significance: We identified the BMPCs as alternative stromal targets of Hh-ligand in PDAC suggesting that the
tumor vasculature is an attractive therapeutic target of Hh blockade. Our data is consistent with the emerging concept that
BM-derived cells make important contributions to epithelial tumorigenesis.
Citation: Nakamura K, Sasajima J, Mizukami Y, Sugiyama Y, Yamazaki M, et al. (2010) Hedgehog Promotes Neovascularization in Pancreatic Cancers by Regulating
Ang-1 and IGF-1 Expression in Bone-Marrow Derived Pro-Angiogenic Cells. PLoS ONE 5(1): e8824. doi:10.1371/journal.pone.0008824
Editor: Sudha Agarwal, Ohio State University, United States of America
Received October 11, 2009; Accepted January 1, 2010; Published January 21, 2010
Copyright:  2010 Nakamura et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by a grant to Y.M. from the New Energy and Industrial Technology Development Organization of Japan (07A05010a). The
funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: mizu@asahikawa-med.ac.jp
. These authors contributed equally to this work.
Introduction
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading
cause of cancer-related death in the United States and fifth in Japan,
and its overall 5-year survival rate is only 5.0–9.7% [1,2].
Gemcitabine-based chemotherapy for locally advanced or metastatic
PDAC has only modest activity with a small survival benefit [3]. The
identification of new molecular targets for PDAC to overcome the
dismal prognosis is therefore necessary. Thus far, a range of targeted
therapies against EGFR [4], Ras/MEK [5] and VEGF [6] have
failed to improve survival significantly in clinical trials.
Aberrant activation of the hedgehog (Hh) pathway has more
recently been recognized as one of the mediators of PDAC
development and is therefore considered to be a promising target
for therapy [7,8]. Hh is a morphogen required for proper pattern
formation during embryogenesis. Elevated expression of Hh-
related proteins, sonic hedgehog (Shh) or indian hedgehog (Ihh),
impairs pancreatic morphogenesis with increases in mesenchyme
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tight regulation of the overall level of Hh activity is crucial for
normal pancreatic development. Since Shh is misexpressed not
only in PDAC but also in the precursor lesions pancreatic
intraepithelial neoplasm (PanIN) [8] and intraductal papillary
mucinous neoplasia [10], dysregulation of this pathway may play a
role during early stages of tumorigenesis. A number of Hh-target
genes, such as Bmp [11], FOXM1 [12], and PMP22 [13], are
overexpressed in PDAC, and there is cross-talk between oncogenic
pathways including MAPK/ERK, PI3K/Akt [14], Wnt [15],
TGFb/BMP [16] and Hh signaling. Among the molecules that
participate in the Hh signaling, Smoothened (Smo) has been
recognized as a key mediator of the signaling; it is one of the
receptor components for Hh ligand and converts Gli2 into a
transcriptional activator [17]. Thus, Smo is a particularly
promising target for anti-cancer therapy [18]. Cyclopamine, a
natural steroid alkaloid, has strong inhibitory effects against Smo
[18] and treatment with cyclopamine in the experimental setting
inhibits growth of many cancers [19,20,21]. Cyclopamine
derivatives with various structural motifs have been generated
and show promise for possible clinical use [22].
Specifically, several studies have demonstrated significant
growth inhibition of PDAC in vivo by Hh pathway blockade
[7,23]. The tumor growth inhibitory mechanism has been thought
to be primarily mediated through blocking an autocrine loop that
might be required for proliferation [7], survival [8] and motility
[21] of cancer cells. However, Smo deletion in the pancreatic
epithelium does not impair tumorigenesis in a mouse model of
PDAC [24], and Hh ligands do not induce transcriptional
reporters of the pathway in PDAC lines. Moreover, transgenic
expression of an activated Smo allele in the pancreatic epithelium
fails to induce Smo pathway target genes or to induce neoplastic
change [25]. Consequently, it has been speculated that Hh
signaling might play a paracrine role within the tumor
microenvironment, in epithelial cancers that lack mutations in
Hh signaling components. Indeed, studies performed by us and
others have defined crucial roles of cancer cell derived Hh on cell
types within tumor stromal compartments [26,27,28]. Despite
these findings, the precise mechanisms by which some tumor cells
are insensitive to Hh inhibition and the stromal cell type(s) that are
responsive to Hh signaling remained unknown. We therefore
undertook studies to elucidate these mechanisms.
Methods
Cell Culture, Protein Analysis, and RNA Analysis
Human PDAC cell lines were obtained from ATCC, Health
Science Research Resources Bank (Osaka, Japan) and Cell
Resource Center for Biochemical Research (Sendai, Japan).
BMMNC isolation, proliferation assays, co-culture, migration
assays, immunoblotting, and qPCR are described in Methods S1.
Primer sequences are summarized in Table S1.
Animals, Bone Marrow Transplantation (BMT) and
Immunohistochemistry
Therapeutic studies with cyclopamine were performed with
nude mice xenografts as described [7]. BMT procedures are
provided in Methods S1. Protocols for animal experiments were
approved by the Asahikawa Medical Collage Institutional Animal
Care and Use Committee.
Tissues were processed as reported previously [26]. Antibodies
and conditions for immunohistochemistry are presented in
Methods S1.
Cellular, Molecular, and Statistical Analyses
Detailed descriptions of procedures are provided in Methods
S1.
Results
In Vivo Effects of Cyclopamine on KP-1N Xenografts
In order to elucidate the mechanisms by which Hh signaling
might support tumor progression in a tumor cell non-
autonomous fashion, we evaluated the role of Hh signaling on
growth of PDAC in vivo.W es e l e c t e dac e l ll i n e ,K P - 1 N ,t h a t
exhibited high expression of Shh but was insensitive to growth
inhibition by cyclopamine in vitro (Figure S1, S2 and Table
S2). Treatment of KP-1N xenografts with cyclopamine daily for
7 days caused a 46-percent reduction in tumor weight as
compared with vehicle control-treated tumors (Figure 1A).
Histopathological analysis revealed that cyclopamine treated
tumors had abundant areas of necrosis resulting in a 59%
reduction in viable tumor weight. In line with these findings,
staining for Ki-67 and TUNEL demonstrated that cyclopamine
treatment reduced proliferation by 14% and increased cell death
by 9% in vivo (Figure 1B); in contrast, there was no significant
effect of cyclopamine on proliferation/cell death kinetics in vitro
(Figure S2).
In order to determine which cells were affected by cyclopamine
treatment, we measured expression of Ptch1 and Gli1 mRNA,
transcriptional targets of Hh signaling, in both the xenografted
human tumor cells as well as the mouse stromal compartment. To
do so, we made use of species-specific probes. We observed that
human Ptch1 and Gli1 in xenograft tissues were only modestly
decreased by cyclopamine treatment (Figure 1C). Comparable,
minor decreases in expression were observed in vitro (Figure S3).
In comparison, mouse Ptch1 and Gli1 mRNA levels showed a
markedly more pronounced downregulation, indicating that
stromal cells are significant targets of Hh blockade. Collectively,
these results indicate that the anti-tumor effect of cyclopamine on
xenograft growth is primarily mediated through a downregulation
of Hh signaling in tumor-associated stroma.
Effects of Cyclopamine on the Tumor Vasculature
Among the stromal components in PDAC xenografts, we were
particularly curious about the tumor vasculature, since we have
demonstrated that BM-derived pro-angiogenic (precursor) cells
are responsive to Hh ligand during neovascularization [26,29].
Therefore, we investigated the effect of cyclopamine on the
tumor vasculature in KP-1N xenografts. Immunostaining for the
endothelial cell marker CD31 revealed that microvascular
density was significantly reduced (42.6%) when mice were
treated with cyclopamine (Figure 2A). The resulting tumor
vasculature was narrowed and fragmented, and the reduction in
mean vessel area was dramatic (64.8%). The inhibition of
angiogenesis by cyclopamine was also observed in Suit-2
xenografts (Figure S4).
Our results suggested that blockade of Hh signaling ‘‘destabi-
lizes’’ the tumor vessels. We wished to confirm this hypothesis by
immunohistochemical staining for a-smooth muscle actin (SMA),
NG2, and CD31. SMA and NG2 are expressed by pericytes,
which are cells that closely associate with CD31-positive
endothelial cells to stabilize blood vessels [30,31]. We observed
50.0% or 62.1% fewer CD31
+ microvessels covered with SMA
+ or
NG2
+ pericytes in the cyclopamine treated tumors (Figure 2B).
Thus, Hh signaling is important for maturation and/or stabiliza-
tion of the tumor vasculature.
Hh Induces Tumor Angiogenesis
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Derived Cells into the Neovasculature
Bone marrow (BM)-derived cells are thought to play a role in
tumor development [32,33]. For instance, various types of BM-
derived hematopoietic cells have been observed to closely associate
with the tumor neovasculature [34,35], and indeed, a small
number of BM-derived progenitor cells were demonstrated to
incorporate into the lumen of a growing vasculature where they
differentiate into endothelial cells in a mouse lung cancer model
[36]. Various factors in the tumor microenvironment can
modulate the recruitment and retention of BM-derived cells
during the development of the tumor vasculature [37]. Therefore,
we sought to determine whether Hh signaling contributes to this
process in PDAC. In order to trace BM-derived cells, we
implanted KP-1N xenografts in chimeric mice with GFP-labeled
BM (GFP-bone marrow transplant model; see Methods). Cyclo-
pamine significantly decreased the recruitment of BM-derived cells
into the xenografts by 60% as compared with control tumors
(Figure 3A).
Among Gli family of transcription factors, control of the
degradation of Gli2 and the processing into its repressor form
define the Hh signaling response [38]. Gli2 protein is processed
and degraded in the absence of Hh ligand, whereas the presence of
Hh ligand promotes Smo enrichment in primary cilia [39],
resulting in nuclear translocation of full length, transcriptionally
competent Gli2 protein [40]. We therefore evaluated the effect of
cyclopamine on Gli2 protein via immunofluorescence analysis
utilizing an antibody against full length form of Gli2 [41] (Figure
S5A). BM-derived cells express full length Gli2 protein and
cyclopamine decreased both the absolute number and the relative
proportion of Gli2 positive BM-derived cells (Figure 3B),
indicating that Hh signaling is activated in BM-derived cells in a
cyclopamine-sensitive (Smo-dependent) manner. Ptch1 protein
was also observed in BM-derived cells as well as in cancer cells and
cyclopamine reduced the Ptch1 expression in stromal compart-
ment (Figure S5B). We failed to demonstrate strong Gli1 protein
expression in the xenograft tissue (data not shown).
In control tumors, GFP-positive BM-derived cells are closely
associated with CD31
+ tumor vessels but they are not incorporated
to the lumen of the vasculatures (Figure 3C). On the other hand,
a subset of BM-derived cells co-expressed VE-cadherin demon-
strating that BM-derived cells are not only recruited to the peri-
vascular area but also give rise directly to the tumor endothelium.
The NG2 proteoglycan is expressed by nascent pericytes during
the early stages of angiogenesis, and a subset of BM-derived cells in
xenograft tumors co-expressed NG2. These results indicate that
BM-derived cells contribute to the development of tumor
vasculature not only by giving rise to specific type of cells but
Figure 1. Hedgehog blockade by cyclopamine inhibits growth of PDAC xenografts in vivo. (A) CD-1 nude mice bearing KP-1N xenografts
were treated with or without cyclopamine (50 mg/kg/day; sc) daily for 7 days (10 xenografts for each group). The results are shown as mean 6 SEM
tumor weight (mg). H-E stainings for xenograft sections are shown and % necrotic area (N) was measured. Scale bars; 200 mm. (B) Xenograft tissues
were stained with anti-Ki-67 (Scale bars; 200 mm) and TUNEL assay (Scale bars; 500 mm) was performed. Quantification of proliferating/apoptotic is
shown as percent positive cells in 5 viable fields from 10 sections. (C) RNA was extracted from xenograft tissue and mRNA levels for Ptch1 and Gli1
were quantified by TaqMan qPCR.
doi:10.1371/journal.pone.0008824.g001
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treatment significantly decreased the integration of the GFP
+ BM-
derived pro-angiogenic cells (BMPCs) into CD31
+, VE-cadherin
+,
or NG2
+ tumor vasculatures. We confirmed that BMPCs were
responsive to Hh since in vitro co-cultures with KP-1N tumor cells
resulted in a cyclopamine-sensitive induction of Gli1/Ptch1
mRNA in BMPCs, but not in the mature endothelial cell line
MS-1 (Figure S6 and data not shown). Taken together, these
results indicate that the Hh pathway plays a role in neovascular-
ization by modulating the incorporation of BM-derived pro-
angiogenic (precursor) cells into the tumor vessels.
Tumor-Derived Hh Promotes Migration of BM-Derived
Pro-Angiogenic Cells In Vitro and In Vivo
We speculated that the decreased numbers of BM-derived cells
in the cyclopamine-treated tumors might be the result of
attenuated mobilization of cells from the BM. However, the
number of circulating BMPCs, as measured by labeling cultured
peripheral blood MNCs with acLDL/isolectin B4 [42], was not
significantly reduced in the presence of cyclopamine (Figure S6).
This finding suggests that Hh might directly regulate recruitment,
differentiation, or migration of precursors for BMPCs within the
tumor microenvironment rather than affecting mobilization of the
precursors from the marrow.
Since inhibition of Hh signaling did not affect mobilization of
the BMPCs, we sought to investigate the mechanisms by which
Hh signaling might enhance their incorporation into the tumor
vasculature. To do so, we examined the effects of Hh signaling on
migration of the precursors. The migration of BMPCs through a
transwell membrane in vitro was measured in the presence of KP-
1N in the lower well. Cultured BMMNCs expressing c-Kit,
CD11b and VE-cadherin were utilized as the precursors for
BMPCs (Figure S6). The number of the BMPCs migrating to the
bottom side of the membrane was significantly increased when co-
cultured with KP-1N as compared with the pro-angiogenic cells
without KP-1N, implying that secreted factors from the PDAC
cells can enhance the migration of the precursors (Figure 4A).
Consistent with a role for the Hh-Smo pathway, preconditioning
the BMPCs with cyclopamine dramatically reduced their ability to
migrate in a dose dependent manner (Figure 4A). To directly
address the role of Smo-dependent signaling in BM-derived pro-
angiogenic cells, we used the BM cells infected with an shRNA
lentivirus targeting Smo (Figure 4B). Suppression of Smo
significantly attenuated their migration to KP-1N tumor cells.
The role of tumor-derived Shh in migration of the precursors was
also confirmed by using a Shh neutralizing antibody (Figure 4C).
In order to elucidate the effects of Smo pathway modulation on
migration of the BMPCs in vivo, we performed matrigel plug
assays. When concentrated supernatant from KP-1N cells mixed
with matrigel was implanted subcutaneously into nude mice, the
number of host cells migrating into the matrigel was significantly
increased, and the cells formed a cord-like structure, mimicking
capillary morphogenesis in vivo (Figure 5A). In order to distinguish
BM-derived cells from other stromal cells, the experiment was
repeated by utilizing other chimeric mice that underwent BMT.
Since we observed significant Tie2 mRNA expression in the BM-
Figure 2. Cyclopamine inhibits the tumor angiogenesis. (A) KP-1N xenografts treated with or without cyclopamine were stained with CD31.
Scale bars; 500 mm. The data are shown as mean 6 SEM MVD and mean vessel area. (B) Double immunofluorescent staining with a-smooth muscle
actin (SMA) with CD31 or NG2 with CD31. Scale bars; 200 mm. The number of CD31
+ microvessels covered with a-SMA or NG2 positive pericytes is
shown.
doi:10.1371/journal.pone.0008824.g002
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shown), Tie2/LacZ mice were used as donor for the BMT [42]. A
large fraction of the cells within matrigel originated from BM as
reflected by positive immunostaining for b-gal (Figure 5B). The
migration of host cells into matrigel plugs was attenuated
significantly when cyclopamine was added to the matrigel. A
similar result was also obtained using an anti-Shh antibody (data
not shown).
Collectively, our results demonstrate that inhibition of tumor-
derived Hh signaling leads to inhibition of tumor angiogenesis and
destabilization of vasculature with a concomitant decrease in
recruitment of BMPCs into the tumor stroma.
Regulation of Pro- and Anti-Angiogenic Factors by Hh
Signaling
To identify the molecular basis of the vascular disruption by Hh
blockade, we quantified the mRNA expression levels of pro- and
anti-angiogenic factors in PDAC xenografts using species-specific
primer/probe sets for qPCR. Specifically, we were curious to
know the levels of VEGF and SDF-1, which are considered pro-
angiogenic factors due to their demonstrated effects on the
recruitment and retention of the pro-angiogenic precursor cells at
sites of tumor formation [34,43].
We found that human VEGF and SDF-1 mRNA expression
were decreased by 31% and 33%, respectively, in the cyclopa-
mine-treated tumors (Figure S7). These results are in contrast to
the modest downregulation of VEGF and SDF-1 mRNA in
cyclopamine-treated KP-1N cells in vitro, either in normoxic or
hypoxic conditions (Figure S8). Likewise, HIF-1a stability was
not affected under hypoxic conditions in vitro. Moreover, blocking
Shh by neutralizing antibody did not cause a reduction in VEGF
mRNA in KP-1N cells, suggesting that autocrine Shh signaling
does not impart an angiogenic phenotype directly on the KP-1N
(Figure S8). Instead, these collective results suggest that Hh
signaling impinges upon the stroma and that stromal-derived
factors might contribute to the expression of VEGF and SDF-1 in
the tumor cells in vivo.
It has been demonstrated that cancer associated fibroblasts
secrete SDF-1 to recruit bone marrow-derived endothelial
Figure 3. Hh promotes the recruitment of BM-derived cells into the tumor vasculature. (A-D) GFP-BMT-chimeric mice bearing KP-1N
xenografts were treated with or without cyclopamine. Recruitment of BM-derived cells into the tumor was tracked by immunostaining with anti-GFP
(A). The data shown as the mean 6 SEM of the numbers of GFP
+ cells. Scale Bars; 100 mm. KP-1N xenograft tissues were immunostained with Gli2 (B),
CD31, VE-cadherin or NG2 (C), in combination with GFP. Scale Bars; 100 mm. Shown are mean 6 SEM of GFP
+ cells recruited to CD31
+ tumor vessels
(upper panel) and number of GFP
+ cells co-localized with CD31, VE-cadherin
+, and NG2 (lower panel).
doi:10.1371/journal.pone.0008824.g003
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angiogenesis [44]. Therefore, we next quantified the expression
of these pro-/anti-angiogenic factors by the murine tumor stroma.
Mouse VEGF and SDF-1 levels were not affected by cyclopamine
in vivo (Figure 6A), indicating that Hh is not involved in the
modulation of these pro-angiogenic factors by tumor stroma.
We next examined the expression of factors that modulate
vascular stability. In the tumors of cyclopamine-treated mice, we
noted a marked reduction in murine Ang-1, IGF-1, and PDGF-B
mRNA, factors known to stabilize the neovasculature. Ang-1 plays
a crucial role during angiogenesis to stabilize neovessels [30], and
its cognate Tie2 receptor is expressed in ECs, pro-angiogenic
monocytes as well as pericyte precursors of mesenchymal origin
[45]. The reduction of Ang-1 was coupled with 86.3% upregula-
tion of Ang-2, a natural antagonist for Tie2, that leads to
dissociation of the mural cell coating to initiate angiogenesis [46]
(Figure S9). In an effort to understand the regulation of these
factors by Hh signaling, we compared their mRNA levels in
BMPCs that were co-cultured with KP-1N cells. Ang-1 and IGF-1
but not PEDF-B mRNA was upregulated by more than 2-fold in a
cyclopamine-sensitive manner (Figure 6B), and simultaneous
downregulation of Ang-2 mRNA in the precursors was observed.
The altered expression of Ang-1 and Ang-2 was canceled by
cyclopamine, and the effect on Ang-1/Ang-2 ratio was dramatic
(54.3% reduction; Figure S9). Consistent results were observed
when we targeted Smo in the BM-derived precursors by lentiviral
shRNA, confirming that the alteration of Ang-1 gene expression
by cyclopamine was due to blockade of Smo-dependent pathway
(Figure 6C). Thus, Hh-dependent Ang-1/Tie2 signaling appears
to be one of the potential mechanisms by which BMPCs stabilize
neovessels.
IGF-1 Is a Target of Hh Signaling in BM-Derived Pro-
Angiogenic Cells
The Reduction in IGF-1 mRNA that we observed in
cyclopamine treated xenografts (Figure 6A) was also recapitulated
in the co-culture assays; i.e., the strong induction of IGF-1 in
BMPCs by KP-1N-derived factors was blocked significantly either
by cyclopamine or shRNA against Smo (Figure 6B, C). To verify
the role of IGF-1 during neovascularization, a tube formation
assay was performed using MS-1 (mouse mature EC line) with
GFP-labeled BM-derived pro-angiogenic precursors (Figure 6D).
Capillary morphogenesis by MS-1 was induced by the BMPCs,
and the effect was enhanced when they were preconditioned in the
presence of KP-1N cells. Strikingly, the effect on capillary
formation was significantly reduced upon treatment with an
anti-IGF-1 neutralizing antibody. Thus, IGF-1 is an important
target of Hh signaling in BM-derived cells, and the downregula-
tion of IGF-1 in tumor xenografts by cyclopamine treatment could
contribute to the disruption of angiogenesis.
Discussion
In the current study, we identified the BM-derived pro-
angiogenic cells (BMPCs) as one of the paracrine targets of Hh,
which plays a critical role to promote tumor angiogenesis and
tumor progression. The destabilized tumor vasculature that we
observed upon cyclopamine treatment first lead us to speculate
that we might observe a reduction in stromal Ang-1 and IGF-1,
factors known to be regulated by Hh pathway [47,48].
Ang-1 develops and stabilizes the primitive vasculature under
Hh signaling in lung branching morphogenesis [49] and Shh
increased the mRNA levels of Ang-1 in fibroblasts, but decreased
Ang-2 [47,50]. Our co-culture experiment demonstrated Ang-1
mRNA in BMPCs was upregulated by soluble factors from KP-1N
in a Smo-dependent manner, suggesting a role of the precursors as
reservoir of Ang-1 in the tumor microenvironment to stabilize
Tie2-expressing ECs as well as subsets of pro-angiogenic cells.
Indeed, a certain fraction of BM-derived cells also express Tie-2
receptor [51], supporting an alternative autocrine or paracrine
effect on the their angiogenic activity by the surrounding stroma
via Ang-1 ligand.
There are various cellular sources of IGF-1 in the tumor stroma,
and the reduction in stroma-derived IGF-1 that we observed may
explain the growth inhibition of PDAC cells in vivo when Hh
signaling was blocked [27]. IGF-1 can also enhance the activity of
BM-derived cells to promote neovascularization through PI3K/
Akt signaling [52]. In the current study, the enhancement of
capillary morphogenesis of MS-1 cells by the BMPCs stimulated
with PDAC cells was clearly attenuated by anti-IGF-1 (Figure 5D).
Figure 4. Shh derived from PDAC cells enhances migration of
BM-derived pro-angiogenic cells in vitro. (A–B) The migration of
BM-derived pre-angiogenic cells (BMPCs) was assessed. BMMNCs
cultured in EGM2-MV medium for 4 days and attached cells were
seeded onto transwell (5 mm pore) coated with 0.1% gelatin, and KP-1N
cells were seeded in the lower well. Number of migrated cells into the
bottom side of the membrane was quantified by DAPI staining after
18 h incubation. The BMPCs were pretreated with Cyclopamine (A),
shRNA lentivirus for Smo (B), and anti-Shh and/or anti-VEGF neutralizing
antibody (C) when seeded onto the well. For a positive control, human
VEGF (50 ng/mL) was added to the lower well, and the BMPCs were
cultured alone as a negative control.
doi:10.1371/journal.pone.0008824.g004
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signaling in the BMPCs and mediates its effect on neovascular-
ization. There was a significant reduction in PDGF-B expression
in the tumor stroma in vivo as well as in BMPCs in vitro; however,
our co-culture assay of BMPCs with KP-1N did not demonstrate
upregulation of PDGF-B mRNA, suggesting that cancer-derived
Hh ligand is unlikely to play a major role in the induction of
PDGF-B. However, the downregulation of PDGF-B by cyclopa-
mine may partially account for the decreased recruitment of
pericytes into newly formed vascular network in xenografts.
The molecular mechanisms that we uncovered here clearly
demonstrate that Hh signaling plays a paracrine role in tumor
progression. It was recently reported that transcriptional induction
of Gli can be maintained independent of Smo [24], and the non-
canonical regulation of Gli-target genes is mediated in part
through TGF-b and Kras signaling. Indeed, most PDAC cells,
including KP-1N, express oncogenic Kras and it has been
demonstrated that TGF-b-Smad pathway is activated in KP-1N
cells [53]. These pathways might account for the modest reduction
of Gli1 transcription by cyclopamine that we observed. It is also
possible that the in vivo growth inhibition by Hh blockade that we
observed might be mediated through an effect on self-renewal
property of rare PDAC initiating cells [54]. However, the
significant change in proliferation/death kinetics that we observed
in a large proportion of cancer cells in the xenografts treated with
cyclopaminewas clearly accompanied by the inhibition of
angiogenesis.
Cyclopamine attenuated not only the recruitment of BM-
derived cells to the tumor but also their incorporation into the
tumor vasculature, supporting an involvement of Hh in the tumor-
associated angiogenesis. Our data do not support the notion that
autocrine signaling of Hh in cancer cells contributes to tumor
angiogenesis, and rather suggest that Hh acts exclusively on the
stroma. Shh has been shown to directly control the activity of
BMPCs cells by stimulating their proliferation, migration and
inducing angiogenic factors to promote vascular remodeling
[26,29,55]. We demonstrated that factors secreted by PDAC cells
can enhance migration of the precursor cells at least in part in a
Smo-dependent manner. There was an additional effect of Hh
signaling on EC assembly through an activation of the BMPCs
together with sprouting mature ECs. We have previously shown
that Shh can enhance the activity of the precursors to promote
capillary morphogenesis by HUVEC [26]. This is probably
mediated through factors ‘‘imported’’ by the pro-angiogenic
Figure 5. Shh derived from PDAC cells enhances recruitment of BM-derived pro-angiogenic cells in vivo. Matrigel plug assay utilizing
Tie2/LacZ-BMT chimeric nude mice. Growth factor reduced matrigel mixed with concentrated conditioned medium from KP-1N (CM
KP-1N) was
transplanted into the chimeric mice. In experimental groups, matrigel was also mixed with cyclopamine. (A) Capillary morphogenesis within the
matrigel was quantified by the number of branch points on H-E sections. (B) Matrigel was immunostained with b-gal. Shown are mean 6 SEM of b-
gal positive cells.
doi:10.1371/journal.pone.0008824.g005
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can differentiate into various cell types in the tumor microenvi-
ronment and the anti-tumor effect of Hh blockade may be
mediated through multiple players in the cancer stroma [33].
Mesenchymal stem cells and immune cells are alternative targets
of Hh [56,57]. In addition, fibroblasts in PDAC desmoplasia could
be important Hh reactive cells [25]. Bailey et al. demonstrated that
fibroblasts in human PDAC were positive for Gli1, and Shh
promoted the proliferation of pancreatic stellate cells and induced
their differentiation into myofibroblasts [28]. A similar conclusion
was reached based on experiments showing that wild type, but not
Smo knockout, mouse embryonic fibroblasts promote the growth
of PDAC xenografts [27]. More recent study by Olive et al.
indicated that IPI-926, a semisynthetic derivative of cyclopamine,
can inhibit proliferation of SMA-positive stromal myofibroblasts,
resulting in a depletion of desmoplastic PDAC stroma [22].
Although they described a transient ‘enhancement’ of tumor
angiogenesis by Smo inhibition, the reduction in SMA
+ myofi-
broblasts may limit the maturation of neovasculature through a
depletion of vascular pericytes, which in turn consequently
‘destabilize’ tumor-associated neovessels as we and others [58]
observed. Further studies are required to monitor the tumor
vessels during longer periods of Hh signaling inhibition in types of
tumor with diverse histological architectures.
Our proposed model for Hh-mediated tumor angiogenesis is
illustratedinFigureS10.The paracrine effectofHhemergesat late
stages of tumorigenesis and regulates neovascularization by acting
through BM-derived cells. Hh ligand stimulates migration/interac-
tion ofthe precursorstoneovessels,whichinturn actas a reservoirof
cytokines to stabilize/maintain the tumor vasculature. The inhibi-
tionofangiogenesisbytargetingSmoisconsistentwithearlierstudies
demonstrating a pro-angiogenic role for Hh on ischemic tissues
Figure 6. Shh derived from PDAC cells induces in Ang-1 and IGF-1 in BM-derived pro-angiogenic cells. (A) mRNA expressions of murine
pro-/anti-angiogenic factors in xenografts were quantified by qPCR. (B, C) Co-culture assay was performed utilizing trenswell. BM-derived pro-angiogenic
cells (BMPCs)wereinfectedwitha lentivirus expressingcontrol shRNAorSmo shRNA and co-culture withKP-1N cells seeded ontotranswell (0.4 mm). RNA
was harvested from the BMPCs 12 h after for qPCR (normalizedtothe cells without KP-1N). (D) Tube formation assay was performedbyculturing MS-1on
matrigel in the presence or absence of GFP-labeled BMPCs. Capillary morphogenesis was observed after 8 h incubation with or without anti-IGF-1
neutralizing antibody. Scale bar, 500 mm. Number of branch points and incorporation of the BMPCs into tube was quantified.
doi:10.1371/journal.pone.0008824.g006
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Hh could also contribute to the activation of stromal myofibroblasts
(potentially derived from the BM) that promote tumorigenesis
through supporting angiogenesis or other mechanisms [22].
However, so far the possibility that Hh signaling may affect on
pre-existing vascular cells as well still exists. In addition, the potential
early cell-autonomous role needs further investigation since it is not
easily reconciled with the dispensability of epithelial Smo expression
for PanIN initiation and progression [24].
Together with recent studies [24,27,28], it is becoming clear
that a paracrine effect of Hh is crucial for tumorigenesis.
Activation of the Hh pathway is important for the stromal cells,
rather than aberrant proliferation of cancer cells. We have
identified a novel aspect of Hh as a late mediator to support the
tumor microenvironment, which promotes the development of the
tumor vasculature in a paracrine manner, and this is mediated by
a significant effect on BM-derived pro-angiogenic cells.
Supporting Information
Methods S1 Supplementary methods.
Found at: doi:10.1371/journal.pone.0008824.s001 (0.12 MB
DOC)
Figure S1 Expression of Hh signaling components. Quantitative
RT-PCR profiling of Hh pathway genes was assessed by Taqman
assay.
Found at: doi:10.1371/journal.pone.0008824.s002 (0.73 MB TIF)
Figure S2 Effects of cyclopamine on human PDAC cell prolifer-
ation/death in vitro. (A) Cell proliferation assay was performed in the
presence of cyclopamine. (B) KP-1N and Suit-2 cells were cultured
with cyclopamine for 7 days. The culture medium containing fresh
cyclopamine was changed every 2 days. (C) Annexin V flow cytometry
analysis. KP-1N cells were treated with 1–10 mMc y c l o p a m i n ef o r
24 hours. The early apoptotic fraction was quantified as FITC-
Annexin V+/PI- fraction (indicated by red frame).
Found at: doi:10.1371/journal.pone.0008824.s003 (5.75 MB TIF)
Figure S3 Reduction of Gli1/Gli2 mRNA levels by cyclopamine
in pancreatic cancer cells in vitro. KP-1N and Suit-2 cells were
treated with 1–10 mM of cyclopamine (cyclo) for 8 hours and Gli1
and Gli2 mRNA expression was quantified.
Found at: doi:10.1371/journal.pone.0008824.s004 (0.51 MB TIF)
Figure S4 Cyclopamine inhibits growth and tumor angiogenesis
of Suit-2 xenogtafts. CD-1 nude mice bearing Suit-2 xenografts
were treated with or without cyclopamine (50 mg/kg/day,
dissolved in PBS containing 10% 2-hydroxylpropyl-h-cyclodextrin
at a concentration of 2.5 mg/mL) administrated by oral daily for 7
days (6 xenografts for each group). The results are shown as mean
6 SEM tumor weight (mg). Sections were stained with anti-CD31.
Scale bars; 500 mm. The data are shown as mean 6 SEM MVD
and mean vessel area.
Found at: doi:10.1371/journal.pone.0008824.s005 (0.88 MB TIF)
Figure S5 Downregulation of full length Gli2 and Ptch1
expression in stroma by Hedgehog blockade. (A) KP-1N
xenografts treated with or without cyclopamine were stained with
anti-Gli2 antibody (Abcam, ab26056 and SantaCruz, G-20). (B)
KP-1N xenograft tissues on GFP-BMT-chimeric mice were
immunostained with Ptch1 in combination with GFP. The results
shown are mean number of GFP+ BM-derived cells positive and
negative for Ptch1. Scale bars; 100 mm.
Found at: doi:10.1371/journal.pone.0008824.s006 (9.54 MB TIF)
Figure S6 Characterization of cultured BM-derived pro-angio-
genic cells. BMMNCs cultured with EGM2-MV medium (10%
FBS) in vitronectin-coated dish were utilized as BM-derived pro-
angiogenic cells (BMPCs) for in vitro experiments. (A) After 4–7
days culture, spindle shaped attached cells were incubated with
acetylated LDL (acLDL; DiI labeled) and labeled with BS1-lectin
(FITC-conjugated). Flow cytometric analysis of attached cells on
day 7. Data show the percentage of positive cells for progenitor
and endothelial markers. (B) BMPCs were seeded in the lower well
and co-cultured with KP-1N cells in the upper well in the presence
or absence of 10 mM cyclopamine. RNA was harvested from the
BMPCs 12 h after for qPCR analysis (normalized to the cells
without KP-1N). (C) Circulating BMPCs in KP-1N xenograft-
bearing mice are quantified. MNCs from 500 mL blood were
cultured with EGM2-MV medium for 4 days and labeled
with DiI-acLDL/FITC-isolectin B4. The results shown as the
mean 6 SEM number of circulating BMPCs (double positive
cells/field).
Found at: doi:10.1371/journal.pone.0008824.s007 (1.98 MB TIF)
Figure S7 Cyclopamione downregulate human VEGF and
SDF-1 in KP-1N xenografts. mRNA expressions of human
pro-/anti-angiogenic factors in xenografts were quantified by
qPCR.
Found at: doi:10.1371/journal.pone.0008824.s008 (0.41 MB TIF)
Figure S8 Hedgehog blockade does not reduce VEGF and SDF-
1 mRNA expression in KP-1N cells in vitro. (A) KP-1N were
treated with 1–10 mM cyclopamine for 1 h and then cultured
either in normoxic (20% O2) or hypoxic (1% O2) conditions.
Protein lysates were harvested after 8 h incubation to detect HIF-
1a protein by western blotting. Immunoblot analysis for anti-HIF-
1a (clone 54, 1:250, BD) and b-actin (1:5000, Sigma) was
performed. (B, C) Total RNA was extracted after 8 h incubation
with 1–10 mM cyclopamine or 1–10 mg/mL anti-Shh (MAB4641;
R&D systems) under normoxic or hypoxic conditions to quantify
VEGF and SDF-1 mRNA by qPCR.
Found at: doi:10.1371/journal.pone.0008824.s009 (1.10 MB TIF)
Figure S9 VEGF, Ang-2 and PDGF-B expression in BM-
derived pro-angiogenic cells was downregulated by cyclopamine.
(A and B) Mouse BM-derived pro-angiogenic cells (BMPCs) were
co-cultured with KP-1N utilizing transwell (0.4 mm pore). BMPCs
were seeded on lower well and KP-1N cells on upper well. mRNA
levels for mouse VEGF (A) Ang-1/Ang-2 (B), and PDGF-B (C) in
the BMPCs were quantified by qPCR after 12 h co-culture with or
without 10 mM cyclopamine (normalized to the BMPCs without
KP-1N).
Found at: doi:10.1371/journal.pone.0008824.s010 (0.52 MB TIF)
Figure S10 Proposed model for Hh-mediated angiogenesis in
PDAC. Shh is an early mediator for pancreatic tumorigenesis, but
it may not be sufficient for proliferation of cancer cells at late
stages. The paracrine effect of Hh emerges during tumorigenesis
by acting through BM-derived cells including pro-agiogenic
(precursor) cells and contributing to the development and
maintenance of the tumor vasculature. Hh could also contribute
to the activation of stromal fibroblasts (potentially derived from the
BM) that potentially promote tumorigenesis through supporting
angiogenesis or other mechanisms.
Found at: doi:10.1371/journal.pone.0008824.s011 (0.74 MB TIF)
Table S1
Found at: doi:10.1371/journal.pone.0008824.s012 (0.05 MB
DOC)
Table S2
Found at: doi:10.1371/journal.pone.0008824.s013 (0.04 MB
DOC)
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